Data_Sheet_5_LncRNA MSC-AS1 Is a Diagnostic Biomarker and Predicts Poor Prognosis in Patients With Gastric Cancer by Integrated Bioinformatics Analysis.CSV

Numerous studies have shown that long uncoded RNA (lncRNA) MSC-AS1 may play an important role in the occurrence and development of some types of cancer. However, its role in gastric cancer has rarely been discussed. This study aimed to clarify the association between lncRNA MSC-AS1 and gastric cancer using The Cancer Genome Atlas (TCGA) database. We determined the expression of MSC-AS1 using the Wilcoxon rank sum test; in addition, logistic regression was applied to evaluate the association between MSC-AS1 and clinicopathological characteristics. Also, Kaplan-Meier and Cox regression were used to evaluate the relationship between MSC-AS1 and survival. A nomogram was conducted to predict the impact of MSC-AS1 on prognosis. Moreover, Gene Set enrichment analysis (GSEA) was performed to annotate the biological function of MSC-AS1. Quantitative analysis of immune infiltration was carried out by single-set GSEA (ssGSEA). The MSC-AS1 level was elevated in gastric cancer tissues. An increased MSC-AS1 level was significantly correlated with T stage (odds ratio [OR] = 2.55 for T3 and T4 vs. T1 and T2), histological type (OR = 5.28 for diffuse type vs. tubular type), histological grade (OR = 3.09 for grade 3 vs. grades 1 and 2), TP53 status (OR = 0.55 for mutated vs. wild type), and PIK3CA status (OR = 0.55 for mutated vs. wild type) (all p < 0.05) by univariate logistic regression. Kaplan-Meier survival analysis showed high MSC-AS1 expression had a poor overall survival [hazard ratio (HR) = 1.75; 95% confidence interval (CI): 1.25–2.45; p = 0.001] and progression-free interval (HR = 1.47; 95% CI: 1.03–2.10; p = 0.034). Multivariate survival analysis revealed that MSC-AS1 expression (HR = 1.681; 95% CI: 1.057–2.673; p = 0.028) was independently correlated with overall survival. GSEA demonstrated that the P38/MAPK pathway, the VEGF pathway, the cell adhesion molecules cams, the NOD-like receptor signaling pathway were differentially enriched in the high MSC-AS1 expression phenotype. SsGSEA and Spearman correlation revealed the relationships between MSC-AS1 and macrophages, NK cells, and Tems were the strongest. Coregulatory proteins were included in the PPI network. Upregulated lncRNA MSC-AS1 might be a potential biomarker for the diagnosis and prognosis of gastric cancer.

众多研究业已证实，长链未编码RNA（lncRNA）MSC-AS1可能在某些类型癌症的发生和发展中扮演着至关重要的角色。然而，其在胃癌中的作用却鲜有论及。本研究旨在借助癌症基因组图谱（TCGA）数据库，阐明lncRNA MSC-AS1与胃癌之间的关联。我们通过威尔科克斯秩和检验确定了MSC-AS1的表达水平；此外，运用逻辑回归模型评估MSC-AS1与临床病理特征之间的关联。同时，采用卡普兰-梅耶生存分析和Cox回归分析评价MSC-AS1与生存率之间的关系。构建诺曼图以预测MSC-AS1对预后的影响。此外，通过基因集富集分析（GSEA）注释MSC-AS1的生物学功能。通过单基因集富集分析（ssGSEA）进行免疫浸润的定量分析。研究发现，胃癌组织中MSC-AS1水平升高。单因素逻辑回归分析显示，MSC-AS1水平的升高与T分期（T3和T4期与T1和T2期相比，比值比[OR]为2.55）、组织学类型（弥漫型与管状型相比，OR为5.28）、组织学分级（3级与1级和2级相比，OR为3.09）、TP53状态（突变型与野生型相比，OR为0.55）和PIK3CA状态（突变型与野生型相比，OR为0.55）（所有p值均小于0.05）显著相关。卡普兰-梅耶生存分析表明，高表达MSC-AS1与较差的总生存率[风险比（HR）=1.75；95%置信区间（CI）：1.25–2.45；p=0.001]和无进展生存期（HR=1.47；95% CI：1.03–2.10；p=0.034）密切相关。多因素生存分析揭示了MSC-AS1表达（HR=1.681；95% CI：1.057–2.673；p=0.028）与总生存率独立相关。GSEA显示，P38/MAPK通路、VEGF通路、细胞粘附分子camps、NOD样受体信号通路在高MSC-AS1表达表型中差异富集。ssGSEA和斯皮尔曼相关性分析揭示了MSC-AS1与巨噬细胞、自然杀伤细胞和Tems之间的关系最为显著。核心调节蛋白被纳入蛋白质互作网络（PPI）。上调的lncRNA MSC-AS1可能成为胃癌诊断和预后评估的潜在生物标志物。